Ixekizumab, and other antibodies that target interleukin 17 monoclonal antibody (IL-17A), may reduce reactivations of tuberculosis in patients with latent tuberculosis infection (LTBI), according to a study research published in the Journal of the American Academy of Dermatology.

-- Xpert^® MTB/XDR cartridge enables expanded drug-resistance profiling in less than 90 minutes
-- Used to empower clinicians to quickly prescribe treatment regimens for multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), the test could help fill a critical gap that is currently jeopardizing global TB targets

A novel mouse model of the protective effects of contained tuberculous infection could lead to the development of a more effective vaccine, according to a study published July 16 in the open-access journal PLOS Pathogens by Alan Diercks of Seattle Children's Research Institute, and colleagues.

The London School for Hygiene and Tropical Medicine is running a survey on identifying and mitigating the impact of COVID-19 on TB and HIV programs. For further information and to access the survey, click here.

The Stop TB Partnership’s TB REACH announced approval of 13 new Wave 8 projects to engage private providers in the fight against TB for a total of USD 5.7 million. 

The approach, which combines a simple-to-use molecular test with the minimally invasive autopsy, could be a valuable tool in regions with high burden of the disease

Aidspan: Global Fund Observer

TB CAB Access Considerations Statement Regarding Johnson & Johnson Announcement of Bedaquiline Price Reduction

But there is still an opportunity to substantially reduce the death toll by prioritising the most critical services, specifically antiretroviral therapy for HIV, timely TB diagnosis and treatment, and provision of long-lasting insecticide-treated nets for malaria, researchers say.